SOPHiA GENETICS (SOPH) to Release Earnings on Tuesday

Key Points

• SOPHiA GENETICS is scheduled to report its Q2 2025 earnings on August 5th, with expectations of a loss of $0.25 per share and revenue of $17.49 million.
• The company's latest earnings report on May 6th showed a loss of $0.26 per share, missing estimates, despite revenue exceeding expectations at $17.78 million.
• SOPHiA GENETICS stock has recently dropped 6.7%, currently trading at $3.36 with a market capitalization of $224.08 million.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $17.49 million for the quarter. SOPHiA GENETICS has set its FY 2025 guidance at EPS.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 98.51% and a negative return on equity of 63.47%. The company had revenue of $17.78 million during the quarter, compared to analyst estimates of $16.76 million. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SOPHiA GENETICS Trading Up 1.4%

NASDAQ SOPH traded up $0.05 during trading hours on Friday, reaching $3.18. The company had a trading volume of 23,535 shares, compared to its average volume of 70,811. The stock has a 50-day moving average of $3.19 and a 200 day moving average of $3.27. SOPHiA GENETICS has a 1-year low of $2.58 and a 1-year high of $4.92. The company has a current ratio of 3.11, a quick ratio of 2.94 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $211.74 million, a P/E ratio of -3.18 and a beta of 1.00.

Institutional Trading of SOPHiA GENETICS

An institutional investor recently raised its position in SOPHiA GENETICS stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) by 246.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,632,871 shares of the company's stock after purchasing an additional 5,432,871 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 11.45% of SOPHiA GENETICS worth $25,341,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.